Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 104

1.

Checkpoint inhibitors and progressive multifocal leukoencephalopathy: friends of foes?

Focosi D, Tuccori M, Maggi F.

Ann Transl Med. 2019 Dec;7(Suppl 8):S298. doi: 10.21037/atm.2019.11.07. No abstract available.

2.

Assessment of prevalence and load of torquetenovirus viremia in a large cohort of healthy blood donors.

Focosi D, Spezia PG, Macera L, Salvadori S, Navarro D, Lanza M, Antonelli G, Pistello M, Maggi F.

Clin Microbiol Infect. 2020 Jan 20. pii: S1198-743X(20)30036-7. doi: 10.1016/j.cmi.2020.01.011. [Epub ahead of print]

PMID:
31972321
3.

Lack of Marseillevirus DNA in immunocompetent and immunocompromised Italian patients.

Macera L, Spezia PG, Focosi D, Mazzetti P, Antonelli G, Pistello M, Maggi F.

J Med Virol. 2020 Feb;92(2):187-190. doi: 10.1002/jmv.25592. Epub 2019 Sep 15.

PMID:
31498443
4.

Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab.

Focosi D, Tuccori M, Maggi F.

Rev Med Virol. 2019 Nov;29(6):e2077. doi: 10.1002/rmv.2077. Epub 2019 Aug 1. Review.

PMID:
31369199
5.

Low prevalence of Gemycircularvirus DNA in immunocompetent and immunocompromised subjects.

Macera L, Spezia PG, Medici C, Falasca F, Sciandra I, Antonelli G, Focosi D, Pistello M, Maggi F.

New Microbiol. 2019 Apr;42(2):118-120. Epub 2019 Apr 29.

6.

Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence.

Macera L, Spezia PG, Medici C, Rofi E, Del Re M, Focosi D, Mazzetti P, Navarro D, Antonelli G, Danesi R, Pistello M, Maggi F.

J Med Virol. 2019 Apr 19. doi: 10.1002/jmv.25488. [Epub ahead of print]

PMID:
31002743
7.

Kinetics of Alphatorquevirus plasma DNAemia at late times after allogeneic hematopoietic stem cell transplantation.

Albert E, Solano C, Giménez E, Focosi D, Pérez A, Macera L, Piñana JL, Mateo EM, Boluda JCH, Maggi F, Navarro D.

Med Microbiol Immunol. 2019 Apr;208(2):253-258. doi: 10.1007/s00430-019-00586-w. Epub 2019 Mar 9.

PMID:
30852649
8.

Torque teno virus monitoring in transplantation: The quest for standardization.

Focosi D, Maggi F.

Am J Transplant. 2019 May;19(5):1599-1601. doi: 10.1111/ajt.15194. Epub 2018 Dec 17. No abstract available.

PMID:
30468687
9.

Early Post-Transplant Torquetenovirus Viremia Predicts Cytomegalovirus Reactivations In Solid Organ Transplant Recipients.

Maggi F, Focosi D, Statzu M, Bianco G, Costa C, Macera L, Spezia PG, Medici C, Albert E, Navarro D, Scagnolari C, Pistello M, Cavallo R, Antonelli G.

Sci Rep. 2018 Oct 19;8(1):15490. doi: 10.1038/s41598-018-33909-7.

10.

Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation.

Albert E, Torres I, Talaya A, Giménez E, Piñana JL, Hernández-Boluda JC, Focosi D, Macera L, Maggi F, Solano C, Navarro D.

J Med Virol. 2018 Sep;90(9):1438-1443. doi: 10.1002/jmv.25218. Epub 2018 May 25.

PMID:
29727487
11.

Induced Pluripotent Stem Cell-Derived Red Blood Cells and Platelet Concentrates: From Bench to Bedside.

Focosi D, Amabile G.

Cells. 2017 Dec 27;7(1). pii: E2. doi: 10.3390/cells7010002. Review.

12.

Dynamics of Torque Teno virus plasma DNAemia in allogeneic stem cell transplant recipients.

Albert E, Solano C, Pascual T, Torres I, Macera L, Focosi D, Maggi F, Giménez E, Amat P, Navarro D.

J Clin Virol. 2017 Sep;94:22-28. doi: 10.1016/j.jcv.2017.07.001. Epub 2017 Jul 8.

PMID:
28710997
13.

Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.

Kast RE, Hill QA, Wion D, Mellstedt H, Focosi D, Karpel-Massler G, Heiland T, Halatsch ME.

Tumour Biol. 2017 May;39(5):1010428317699797. doi: 10.1177/1010428317699797. Review.

PMID:
28459367
14.

Advances in Pretransplant Donor-Specific Antibody Testing in Solid Organ Transplantation: From Bench to Bedside.

Focosi D.

Int Rev Immunol. 2016 Jul 3;35(4):351-368. Epub 2016 Apr 27. Review.

PMID:
27120091
15.

Tweaking Mesenchymal Stem/Progenitor Cell Immunomodulatory Properties with Viral Vectors Delivering Cytokines.

Quaranta P, Focosi D, Freer G, Pistello M.

Stem Cells Dev. 2016 Sep 15;25(18):1321-41. doi: 10.1089/scd.2016.0145. Epub 2016 Sep 1. Review.

PMID:
27476883
16.

Cyclovirus Vietnam DNA in immunodeficient patients.

Macera L, Focosi D, Vatteroni ML, Manzin A, Antonelli G, Pistello M, Maggi F.

J Clin Virol. 2016 Aug;81:12-5. doi: 10.1016/j.jcv.2016.05.011. Epub 2016 May 20.

PMID:
27270127
17.

Zika Virus: Implications for Public Health.

Focosi D, Maggi F, Pistello M.

Clin Infect Dis. 2016 Jul 15;63(2):227-33. doi: 10.1093/cid/ciw210. Epub 2016 Apr 5. Review.

PMID:
27048745
18.

Ebolavirus and evidence-based speculations.

Focosi D, Antonelli G, Maggi F.

New Microbiol. 2016 Jan;39(1):71-2. No abstract available.

19.

Effect of Induced Pluripotent Stem Cell Technology in Blood Banking.

Focosi D, Pistello M.

Stem Cells Transl Med. 2016 Mar;5(3):269-74. doi: 10.5966/sctm.2015-0257. Epub 2016 Jan 27. Review.

20.

Human Wharton's jelly-derived mesenchymal stromal cells engineered to secrete Epstein-Barr virus interleukin-10 show enhanced immunosuppressive properties.

Quaranta P, Focosi D, Di Iesu M, Cursi C, Zucca A, Curcio M, Lapi S, Boldrini L, Stampacchia G, Paolicchi A, Scatena F, Freer G, Pistello M.

Cytotherapy. 2016 Feb;18(2):205-18. doi: 10.1016/j.jcyt.2015.11.011.

PMID:
26794713

Supplemental Content

Loading ...
Support Center